Key Highlights
- Net income was USD 3.9 million for the third quarter of 2026, versus a net loss of USD 8.8 million a year earlier, after a USD 6.3 million loss from operations.
- Fair value gains of USD 7.5 million on Warrant liabilities and USD 3.4 million on derivative liabilities produced total other income of USD 10.3 million.
- Total Revenue was USD 56 thousand, up from USD 15 thousand, and Research and Development expense rose to USD 4.4 million from USD 3.5 million.
- Cash and equivalents were USD 9.9 million at September 30, 2026, against a stockholders' Deficit of USD 14.8 million and nine-month operating cash outflow of USD 11.7 million.
A Quarterly Profit Built on Non-Cash Fair Value Gains
Clene (NASDAQ:CLNN) filed its 10-Q on November 4, 2026 for the quarter ended September 30. Product revenue was USD 43 thousand and Royalty revenue USD 13 thousand, while operating expenses were USD 6.4 million, giving a loss from operations of USD 6.3 million. Net Income of USD 3.9 million came from other income of USD 10.3 million, mostly non-cash changes in the fair value of warrant and derivative liabilities. Basic Earnings Per Share were USD 0.30 and Diluted Earnings per Share were USD 0.05, against a loss of USD 0.85 a year earlier. Excluding those gains the Business remains loss-making.
Nine-Month Loss, Warrants and the January Offering
The clinical-stage company develops nanocrystal-based drug candidates on a clean-surfaced nanotechnology platform. For nine months it reported a net loss of USD 17.6 million, or USD 1.42 per share, versus USD 16.9 million, or USD 1.77. The period includes a USD 4.6 million loss on initial issuance of Equity from a January 2026 public offering that carried Series A warrants, exercisable for 1.2 shares each, and Series B warrants, exercisable for 2.8 shares each. Net proceeds from stock and warrants were USD 16.7 million. Shares outstanding rose to 14,213,981 from 10,849,974 at the end of 2025.
Thin Cash, Convertible Debt and Liquidity Risk
Operating cash use was USD 11.7 million over nine months, so USD 9.9 million of cash does not cover a full year at that pace. Current liabilities were USD 17.1 million, including USD 8.0 million of convertible notes and USD 5.0 million of notes payable, while warrant and derivative liabilities total USD 11.0 million. The filing lists the ability to continue as a Going Concern and plans to raise additional funding among its forward-looking topics. For Clene (NASDAQ:CLNN), a small share count and thin trading mean a few trades can move the price, spreads can be wide and quoted moves can reverse. Fair value gains can swing back as the share price changes.
Where Things Stand
The profit came from accounting gains, not from operations. Clene (NASDAQ:CLNN) lost USD 6.3 million from operations in the quarter, yet remeasurement of warrant and derivative liabilities added USD 10.9 million of non-cash gains, leaving net income of USD 3.9 million. Nine-month results show the underlying position, a net loss of USD 17.6 million. With USD 9.9 million of cash and a USD 14.8 million stockholders' deficit, further financing looks central to the outlook. Next markers are the cash burn rate, convertible note maturities and clinical trial updates, none of which are detailed in this extract.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...